Fraunhofer-Institut für Toxikologie und Experimentelle Medizin

BIO-Europe 2026

Partneringkonferenz der Biotechnologiebranche / 09. November 2026 - 11. November 2026

BIO-Europe – internationales Branchentreffen

Von humanrelevanten präklinischen Modellen bis zum klinischen Proof of Concept

Treffen Sie unsere Expertinnen und Experten auf der BIO-Europe in Köln und erfahren Sie, wie Fraunhofer ITEM Pharma- und Biotech-Unternehmen entlang der translationalen Arzneimittelentwicklung unterstützt, von präklinischen Wirksamkeits- und Sicherheitsprüfungen bis hin zu frühen klinischen Studien.

Veranstaltungsdetails

Programm

Weitere Informationen zur BIO-Europe 2026 finden Sie auf der Konferenz-Website.

Veranstaltungsort

Köln, Deutschland

Datum

09. November 2026 - 11. November 2026

Diesen Termin als iCal herunterladen

Sprache

Englisch

Unsere Themen auf der BIO-Europe 2026

Human-Relevant Disease Models

Our Organoid & Tissue Research Center at Fraunhofer ITEM brings together native human tissues, organoids and standardized iPSC-derived immune cell models in an integrated platform for preclinical research.

Disease-relevant models for inflammation, fibrosis, infection and other indications provide human-relevant insights into efficacy, safety and mechanisms of action.

Learn more

Inhalation Toxicology

We are committed to provide customized solutions for aerosolization and testing of drug candidates including small molecules, recombinant proteins, cell and gene therapies or bacteriophages.

We are happy to support you as a reliable partner with our key expertise in:

Inhaled administration and (GLP-certified) toxicity assessment
Toxicokinetics of inhaled particles
Formulation analytics

With our inhouse-knowledge of histopathology, hematology and clinical chemistry, as well as our portfolio in safety pharmacology testing, we provide full preclinical service for translation to clinical phase trials.

Toxicology Testing

Translational Fibrosis Research

Advance the preclinical efficacy of antifibrotic therapeutics on human lung tissue for early human proof-of-concept.

Fibrosis Research

Clinical Trials & Proof-of-Concept Studies

We conduct early-phase and proof-of-concept clinical studies and combine clinical research with biomarkers, imaging, respiratory diagnostics and specialized challenge models to support evidence-based development decisions.

Learn More